Breaks Categories: News

TuesdayApr 28, 2026 11:54 am

BioMedNewsBreaks — ARMR Sciences Inc. Advances Fentanyl Vaccine with Private Placement Led by Joseph Gunnar & Co.

ARMR Sciences completed a private placement financing with strategic and institutional investors, with Joseph Gunnar & Co., LLC acting as placement agent, as the company advances toward human trials for its fentanyl vaccine. Backed by the U.S. Department of War, the vaccine is designed to prevent fatal overdoses and address threats from substances such as fentanyl, supporting continued development and clinical progression. To view the announcement, visit https://ibn.fm/t39w2 About ARMR Sciences Inc. ARMR Sciences Inc. is America's biodefense technology company, developing next-generation countermeasures against synthetic drug threats, such as fentanyl. Through its foundational license, ARMR is backed by early-stage research funding from the…

Continue Reading

MondayApr 27, 2026 9:00 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL, NXPLW) Regains Compliance With Nasdaq Minimum Bid Price Requirement

NextPlat (NASDAQ: NXPL, NXPLW) announced it has regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) following receipt of a compliance letter from The Nasdaq Stock Market LLC on April 27, 2026. Nasdaq determined the Company’s shares maintained a closing bid price of at least $1.00 for 10 consecutive business days from April 13, 2026 to April 24, 2026, and confirmed the matter is now closed, with NextPlat continuing to trade on The Nasdaq Capital Market under the ticker NXPL. To view the full press release, visit: https://ibn.fm/RUz3J About NextPlat Corp. NextPlat is a global…

Continue Reading

FridayApr 24, 2026 11:02 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Editorial on Pipeline-Driven Valuation 

Oncotelic Therapeutics (OTCQB: OTLC) is featured in a NetworkNewsAudio Audio Press Release titled “When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech,” which highlights how late-stage drug development assets increasingly drive valuation in the biopharma sector. The editorial, supported by analysis from McKinsey & Company, notes that companies tend to realize the majority of value creation as products approach commercialization, reflecting reduced risk and clearer revenue visibility, a trend directly relevant to Oncotelic’s oncology-focused pipeline and strategic development approach. To view the full press release, visit https://ibn.fm/0uj56 About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy…

Continue Reading

FridayApr 24, 2026 10:48 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Highlights Partnership Strategy to Advance Pipeline

Oncotelic Therapeutics (OTCQB: OTLC) provided a corporate update emphasizing its partnership-driven strategy to advance its oncology and rare disease pipeline and enhance shareholder value. The company cited its joint venture with GMP Biotechnology, which contributed to a $249.0 million increase in its balance sheet based on an independent third-party valuation, and said it is pursuing additional collaborations to support development and commercialization efforts. Management noted the approach is designed to advance multiple drug candidates in parallel while maintaining capital efficiency and unlocking the value of its intellectual property portfolio. To view the full press release, visit https://ibn.fm/gX9eb About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the…

Continue Reading

FridayApr 24, 2026 9:20 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces $2.61M Private Placement and Warrant Inducement 

Scinai Immunotherapeutics (NASDAQ: SCNI) announced it has entered into a securities purchase agreement with institutional and accredited investors for the sale of 5,208,333 ADSs at $0.48 per ADS, along with accompanying Series A and Series B warrants, and separately executed a warrant inducement agreement with an existing investor. The combined transactions are expected to generate approximately $2.61 million in gross proceeds, with closing anticipated on or about April 27, 2026, subject to customary conditions. The company said proceeds will support expansion of its CDMO platform, advancement of customer programs and continued investment in its immunotherapy pipeline. To view the full…

Continue Reading

ThursdayApr 23, 2026 11:24 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured In BioMedWire Editorial On Biotech Valuation Shift 

Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in a BioMedWire editorial examining how advancing drug pipelines are reshaping biotech valuations, as scientific progress is increasingly recognized as a measurable financial asset under evolving accounting frameworks. The piece highlights Oncotelic’s position at the intersection of oncology and AI-driven drug development, noting its diversified pipeline and strategic holdings, including a 45% stake in GMP Bio, as examples of how innovation and clinical advancement are being reflected in tangible enterprise value. To view the full press release, visit https://ibn.fm/JimL6 About Oncotelic Therapeutics Inc. Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is…

Continue Reading

ThursdayApr 23, 2026 9:40 am

BioMedNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Adds Robert Langer, Stephen Brannan To Scientific Advisory Board

This NewsBreak has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced the appointments of Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, strengthening its expertise in biotechnology, drug delivery and central nervous system clinical development as the company advances its pipeline of novel serotonergic agonists. The additions support Helus Pharma’s focus on disciplined, evidence-based drug development, including programs targeting major depressive disorder and generalized anxiety disorder, as it works to address unmet needs in mental health. To view the full press release, visit https://ibn.fm/CyjTq…

Continue Reading

ThursdayApr 23, 2026 9:30 am

BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Highlights Preclinical Immuno-Oncology Data At AACR 2026

Tonix Pharmaceuticals (NASDAQ: TNXP) announced new preclinical data from its immuno-oncology portfolio, including TNX-1700 and TNX-4700, presented through one oral and two poster sessions at the American Association for Cancer Research Annual Meeting 2026 in San Diego. The company reported findings supporting TNX-1700’s potential in reducing inflammation and tumor progression in gastric cancer models and demonstrating favorable pharmacokinetics, while TNX-4700 showed promising in vitro activity targeting BTLA, underscoring its potential as a cancer immunotherapy candidate alone or in combination with other checkpoint inhibitors. To view the full press release, visit https://ibn.fm/Oly6o Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals is a fully-integrated,…

Continue Reading

WednesdayApr 22, 2026 2:54 pm

BioMedNewsBreaks — Perpetuals.com Ltd. (NASDAQ: PDC) Expands BayesShield AI Into Healthcare With Clinical Diagnostic Platform

Perpetuals.com (NASDAQ: PDC) announced the expansion of its BayesShield AI technology into healthcare with the launch of BayesShield Clinical, designed to identify physicians with the strongest diagnostic accuracy across specific case types. The platform applies the company’s statistical methodology, originally developed for financial markets, to reduce bias and improve clinical decision-making, with initial deployment supported through a partnership with the European Institute of Management to oversee pilot programs and academic validation. To view the full press release, visit https://ibn.fm/e91bm About Perpetuals Perpetuals.com Ltd (NASDAQ: PDC) is a fintech company developing AI-powered trading products and prediction markets, with a global footprint across the United States, Europe, and Asia. Its mission is to…

Continue Reading

WednesdayApr 22, 2026 2:34 pm

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives Positive FDA Review Letter Supporting Ketamine ANDA Progress

NRx Pharmaceuticals (NASDAQ: NRXP) announced it received a positive Discipline Review Letter from the FDA Office of Generic Drugs covering quality-related aspects of its ketamine ANDA, with only minor administrative updates requested. The company also reported a supportive meeting with FDA leadership aligned with federal priorities to accelerate treatments for severe mental illness, reinforcing expectations for potential approval of its preservative-free ketamine product in summer 2026. To view the full press release, visit https://ibn.fm/dL8aD About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders,…

Continue Reading